Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05986851 · ClinicalTrials.gov registry record · Phase 2
Azeliragon in MGMT Unmethylated Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by Cantex Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 8
- Study locations
NCT05986851: Active Phase 2 study of Glioblastoma, sponsored by Cantex Pharmaceuticals.
NCT05986851 is a Phase 2 study of Glioblastoma that is active but no longer recruiting, run by Cantex Pharmaceuticals. The registered enrollment target is 30 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (72% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05986851, a Phase 2 study of Glioblastoma, is active but no longer recruiting, sponsored by Cantex Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a phase 2 study to evaluate the safety and preliminary evidence of effectiveness of azeliragon, in combination with radiation therapy, as an initial treatment of a form of glioblastoma. Glioblastoma is a type of brain cancer that grows quickly and can invade and destroy healthy tissue. There's no cure for glioblastoma, which is also known as glioblastoma multiforme. Treatments, including surgery, radiation, and chemotherapy might slow cancer growth and reduce symptoms. New treatments of glioblastoma are needed.
Primary Outcome
Progression-free survival (PFS) of newly diagnosed unmethylated GBM treated with the combination of RT and azeliragon.
Conditions Studied
Interventions
- DRUG Azeliragon
Study Locations (8)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Florida
- Miami Cancer Institute - Baptist Health - Miami
Michigan
- Corewell Health - Royal Oak
Missouri
- Washington University in St. Louis - St Louis
New York
- Lenox Hill Hospital - New York
Oklahoma
- The University of Oklahoma Health Science Center - Oklahoma City
Utah
- University of Utah Health Huntsman Cancer Center - Salt Lake City
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-09-12 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 2 |
What the registry record for NCT05986851 still lists
NCT05986851 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Azeliragon is the first listed.
NCT05986851 lists 8 locations in 8 states (Colorado, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT05986851 about?
NCT05986851 is a clinical study titled "Azeliragon in MGMT Unmethylated Glioblastoma". This is a phase 2 study to evaluate the safety and preliminary evidence of effectiveness of azeliragon, in combination with radiation therapy, as an initial treatment of a form of glioblastoma. Glioblastoma is a type of brain cancer that grows quickly and can invade and destroy healthy tissue. There...
What is the current status of trial NCT05986851?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-09-12. Estimated completion is 2025-06-30.
What conditions does trial NCT05986851 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT05986851?
The interventions under investigation include: Azeliragon (DRUG).
Who is sponsoring clinical trial NCT05986851?
This trial is sponsored by Cantex Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05986851 being conducted?
This trial has 8 study locations across Colorado, Florida, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05986851's enrollment target sits among peer trials
30 124th of 199 higher than 69 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI